A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Assets in oncology and psoriasis are set for upcoming Pdufa decisions.
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.